Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AxoGen, Inc. stock logo
AXGN
AxoGen
$14.16
+1.1%
$11.60
$9.22
$21.00
$644.64M11.90 million shs1.50 million shs
Embecta Corp. stock logo
EMBC
Embecta
$13.32
+4.6%
$10.34
$9.20
$21.48
$744.52M1.08664,816 shs888,956 shs
LENSAR, Inc. stock logo
LNSR
LENSAR
$12.92
-0.8%
$12.90
$3.80
$17.31
$155.51M0.560,265 shs49,998 shs
ZimVie Inc. stock logo
ZIMV
ZimVie
$18.85
+0.1%
$12.46
$8.15
$18.98
$531.02M2.21.25 million shs351,120 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AxoGen, Inc. stock logo
AXGN
AxoGen
+0.79%+11.63%+17.83%+28.77%+27.13%
Embecta Corp. stock logo
EMBC
Embecta
+3.66%+30.03%+21.59%+1.84%-17.28%
LENSAR, Inc. stock logo
LNSR
LENSAR
+1.24%+0.70%0.00%-6.86%+224.13%
ZimVie Inc. stock logo
ZIMV
ZimVie
+0.11%+0.32%+109.22%+111.34%+4.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AxoGen, Inc. stock logo
AXGN
AxoGen
2.5243 of 5 stars
3.51.00.00.03.02.50.6
Embecta Corp. stock logo
EMBC
Embecta
4.7409 of 5 stars
3.23.03.30.03.13.33.8
LENSAR, Inc. stock logo
LNSR
LENSAR
0.6825 of 5 stars
2.01.00.00.01.02.50.0
ZimVie Inc. stock logo
ZIMV
ZimVie
0.9417 of 5 stars
1.05.00.00.02.71.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AxoGen, Inc. stock logo
AXGN
AxoGen
3.00
Buy$26.0083.62% Upside
Embecta Corp. stock logo
EMBC
Embecta
2.33
Hold$19.0042.64% Upside
LENSAR, Inc. stock logo
LNSR
LENSAR
2.00
Hold$15.0016.10% Upside
ZimVie Inc. stock logo
ZIMV
ZimVie
2.00
Hold$17.75-5.84% Downside

Current Analyst Ratings Breakdown

Latest LNSR, EMBC, AXGN, and ZIMV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/31/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$19.00
7/22/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$9.00 ➝ $19.00
7/16/2025
Embecta Corp. stock logo
EMBC
Embecta
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$13.00 ➝ $12.00
5/23/2025
Embecta Corp. stock logo
EMBC
Embecta
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$25.00
5/23/2025
Embecta Corp. stock logo
EMBC
Embecta
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.00
5/15/2025
ZimVie Inc. stock logo
ZIMV
ZimVie
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $10.00
5/13/2025
AxoGen, Inc. stock logo
AXGN
AxoGen
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$26.00 ➝ $24.00
(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AxoGen, Inc. stock logo
AXGN
AxoGen
$203.27M3.21N/AN/A$2.44 per share5.80
Embecta Corp. stock logo
EMBC
Embecta
$1.12B0.69$3.49 per share3.82($11.45) per share-1.16
LENSAR, Inc. stock logo
LNSR
LENSAR
$53.49M2.88N/AN/A($1.93) per share-6.69
ZimVie Inc. stock logo
ZIMV
ZimVie
$449.75M1.18$1.86 per share10.14$14.64 per share1.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AxoGen, Inc. stock logo
AXGN
AxoGen
-$9.96M-$0.10N/AN/AN/A-2.29%-4.43%-2.34%N/A
Embecta Corp. stock logo
EMBC
Embecta
$78.30M$1.439.314.340.717.58%-23.40%14.46%N/A
LENSAR, Inc. stock logo
LNSR
LENSAR
-$31.40M-$4.21N/AN/A-84.49%-737.30%-72.60%8/14/2025 (Estimated)
ZimVie Inc. stock logo
ZIMV
ZimVie
-$25.83M-$0.70N/AN/A-4.39%6.37%3.34%10/29/2025 (Estimated)

Latest LNSR, EMBC, AXGN, and ZIMV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q3 2025
Embecta Corp. stock logo
EMBC
Embecta
$0.7720$1.12+$0.3480$0.78$278.15 million$295.50 million
8/7/2025Q2 2025
LENSAR, Inc. stock logo
LNSR
LENSAR
-$0.0750-$0.15-$0.0750-$0.15$16.55 million$11.36 million
7/30/2025Q2 2025
ZimVie Inc. stock logo
ZIMV
ZimVie
$0.2080$0.26+$0.0520-$0.14$112.60 million$116.66 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AxoGen, Inc. stock logo
AXGN
AxoGen
N/AN/AN/AN/AN/A
Embecta Corp. stock logo
EMBC
Embecta
$0.604.50%N/A41.96%N/A
LENSAR, Inc. stock logo
LNSR
LENSAR
N/AN/AN/AN/AN/A
ZimVie Inc. stock logo
ZIMV
ZimVie
N/AN/AN/AN/AN/A

Latest LNSR, EMBC, AXGN, and ZIMV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/6/2025
Embecta Corp. stock logo
EMBC
Embecta
quarterly$0.155.79%8/29/20258/29/20259/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AxoGen, Inc. stock logo
AXGN
AxoGen
0.59
4.14
2.67
Embecta Corp. stock logo
EMBC
Embecta
N/A
2.47
1.78
LENSAR, Inc. stock logo
LNSR
LENSAR
N/A
1.52
0.88
ZimVie Inc. stock logo
ZIMV
ZimVie
0.56
2.37
1.60

Institutional Ownership

CompanyInstitutional Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
80.29%
Embecta Corp. stock logo
EMBC
Embecta
93.83%
LENSAR, Inc. stock logo
LNSR
LENSAR
40.15%
ZimVie Inc. stock logo
ZIMV
ZimVie
95.63%

Insider Ownership

CompanyInsider Ownership
AxoGen, Inc. stock logo
AXGN
AxoGen
2.78%
Embecta Corp. stock logo
EMBC
Embecta
0.42%
LENSAR, Inc. stock logo
LNSR
LENSAR
66.00%
ZimVie Inc. stock logo
ZIMV
ZimVie
5.41%
CompanyEmployeesShares OutstandingFree FloatOptionable
AxoGen, Inc. stock logo
AXGN
AxoGen
45046.01 million44.73 millionOptionable
Embecta Corp. stock logo
EMBC
Embecta
2,10058.49 million58.20 millionOptionable
LENSAR, Inc. stock logo
LNSR
LENSAR
11011.94 million4.01 millionOptionable
ZimVie Inc. stock logo
ZIMV
ZimVie
1,77028.20 million26.68 millionOptionable

Recent News About These Companies

ZimVie (NASDAQ:ZIMV) Stock Rating Lowered by B. Riley
ZimVie Reports Second Quarter 2025 Financial Results
Insights into ZimVie's Upcoming Earnings
ZimVie to sell to investment firm for about $730M
BC-Most Active Stocks
...

New MarketBeat Followers Over Time

Media Sentiment Over Time

AxoGen stock logo

AxoGen NASDAQ:AXGN

$14.16 +0.15 (+1.07%)
Closing price 04:00 PM Eastern
Extended Trading
$14.06 -0.10 (-0.67%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.

Embecta stock logo

Embecta NASDAQ:EMBC

$13.32 +0.59 (+4.63%)
Closing price 04:00 PM Eastern
Extended Trading
$13.33 +0.01 (+0.08%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

LENSAR stock logo

LENSAR NASDAQ:LNSR

$12.92 -0.11 (-0.84%)
Closing price 04:00 PM Eastern
Extended Trading
$12.90 -0.03 (-0.19%)
As of 04:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

ZimVie stock logo

ZimVie NASDAQ:ZIMV

$18.85 +0.02 (+0.11%)
Closing price 04:00 PM Eastern
Extended Trading
$18.85 0.00 (0.00%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment. The company offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. In addition, the company designs, manufactures, and distributes spinal fusion implants, instrumentation for various spinal procedures, biologics, and bone healing technologies. Further, it provides MIS solutions that deliver implant and instrumentation systems; and motion preservation solutions that offer non-fusion alternatives for cervical disc implant or growth modulation for anterior vertebral body tethering. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Westminster, Colorado.